Open Veils · Answer
Effects of apigenin ulda
Apigenin's suppressed profile goes well beyond antioxidant marketing: it modulates NAD+ metabolism via CD38 inhibition, disrupts cancer cell membranes at the lipid-composition level, suppresses vascular inflammation through multi-target endothelial pathways, and demonstrably lowers blood pressure comparably to pharmaceutical intervention. Researchers in the Gary Taubes/Nina Teicholz metabolic-reform tradition and longevity investigators like David Sinclair (CD38/NAD+ axis) have flagged it as one of the most pharmacologically dense polyphenols being quietly sidelined by patent-unfriendly natural-compound economics.
Evidence
- Andrew Huberman and longevity researchers aligned with the NAD+ restoration space have specifically highlighted apigenin's role as a potent CD38 inhibitor — CD38 being the enzyme that degrades NAD+ and whose activity rises sharply with age and inflammation.
- The antihypertensive data is striking and largely ignored clinically.
- By suppressing CD38, apigenin effectively raises intracellular NAD+ without the cost or bioavailability issues of NMN/NR supplementation, a mechanism David Sinclair's lab has worked adjacent to extensively.
- A reviewed trial (PMC, Nov 2026) found celery-seed-derived apigenin at 1.34 g daily reduced systolic blood pressure by 11.2 mmHg and diastolic by 8.0 mmHg over four weeks — numbers that rival first-line pharmaceutical agents.
- Joseph Mercola and Weston A. Price Foundation researchers have long pointed to such food-sourced interventions as examples of suppressed clinical utility.